Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Valero

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Journal of the National Cancer Institute|February 3, 2000
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinomaG N Hortobagyi, A U Buzdar, R L Theriault, et al.
ESMO Open|August 29, 2025
Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapyA Strahan, Q Jin, A S Raghavendra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†A M Gonzalez-Angulo, A Akcakanat, S Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2001
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trialG N Hortobagyi, N T Ueno, W Xia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapyL Du, C Yau, L Brown-Swigart, et al.
ESMO Open|January 20, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancerF Lynce, C Valenza, S M Niman, et al.
Breast Cancer Research and Treatment|June 13, 2021
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)Kathryn J Ruddy, Yue Zheng, Nabihah Tayob, et al.
Psicothema|July 23, 2021
[Empirically Supported Psychological Treatments for Children and Adolescents: State of the Art]Eduardo Fonseca-Pedrero, Marino Pérez-Álvarez, Susana Al-Halabí, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Journal of the National Cancer Institute|February 3, 2000
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinomaG N Hortobagyi, A U Buzdar, R L Theriault, et al.
ESMO Open|August 29, 2025
Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapyA Strahan, Q Jin, A S Raghavendra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†A M Gonzalez-Angulo, A Akcakanat, S Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2001
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trialG N Hortobagyi, N T Ueno, W Xia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapyL Du, C Yau, L Brown-Swigart, et al.
ESMO Open|January 20, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancerF Lynce, C Valenza, S M Niman, et al.
Breast Cancer Research and Treatment|June 13, 2021
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)Kathryn J Ruddy, Yue Zheng, Nabihah Tayob, et al.
Psicothema|July 23, 2021
[Empirically Supported Psychological Treatments for Children and Adolescents: State of the Art]Eduardo Fonseca-Pedrero, Marino Pérez-Álvarez, Susana Al-Halabí, et al.
Pageof 12